| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Agilent Technologies, Inc.$127.06
+2.73 (+2.2%)
Market Cap
38.14 B
EPS
5.00
P/E Ratio
27.12 $
Value Trade
401.66 M
SEC Financials
Q2 2026Dilution Risk
Revenue
1.83 B
R&D Expenses
126.00 M
Total Assets
13.06 B
Total Liabilities
5.94 B
Equity
7.12 B
D/E Ratio
12,345
2.37 %
Week
-6.44 %
1 Month
-8.18 %
3 Month
-20.43 %
6 Month
-13.35 %
5 Year
275 %
All Time
Cash Data
Cash Position
1.81 B
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
Jun 1, 2026
Overview
Volume
4.33 M
52 Week Range
108.35 - 160.27
% held by Insiders
0.34 %
% held by Institutions
92.37 %
Enterprise Value
39.69 B
Total Shares
282.49 M
Short %
1.85 %
Float Shares
282.21 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in A
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Agilent Technologies, Inc. (A) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
A
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
A
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
A
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
A Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
A Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-11-20 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-11-20 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-11-20 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
AAgilent Receives FDA Approval for Expanded Use of PD-L1 IHC 22C3 pharmDx on Dako Omnis in Esophageal Squamous Cell Carcinoma, Triple-Negative Breast Cancer, Cervical Cancer, and Gastric or Gastroesophageal Junction Adenocarcinoma
Agilent has received FDA approval for the expanded use of its PD-L1 IHC 22C3 pharmDx test on the Dako Omnis platform. This approval covers esophageal squamous cell carcinoma, triple-negative breast cancer, cervical cancer, and gastric or gastroesophageal junction adenocarcinoma. The expanded use of this diagnostic tool is expected to enhance treatment options for patients with these cancers.
Read more →AAgilent Introduces OpenLab Sync to Support Guided, Digital Execution in the Laboratory
Agilent has launched OpenLab Sync, a new platform designed to enhance digital execution in laboratories. This tool aims to support guided workflows and improve laboratory efficiency. The introduction of OpenLab Sync reflects Agilent's commitment to innovation in laboratory technology.
Read more →AAgilent Reports Second-Quarter Fiscal Year 2026 Financial Results
Agilent has released its financial results for the second quarter of fiscal year 2026. The report includes key metrics and performance indicators relevant to the company's fiscal health. However, specific details regarding revenue, profit margins, or future guidance were not provided in the article.
Read more →AAgilent Launches Multi-Attribute Method (MAM) Solution for BioPharma Quality Control
Agilent has introduced a new Multi-Attribute Method (MAM) solution aimed at improving quality control in the biopharmaceutical sector. This innovative approach is designed to enhance the efficiency of biopharma processes, potentially leading to better product quality and compliance. The launch signifies Agilent's commitment to advancing biopharma technologies.
Read more →AAgilent Launches 1290 Infinity III Fluorescence Detector for Confident Trace Analysis at UHPLC Speed
Agilent has introduced the 1290 Infinity III Fluorescence Detector designed for ultra-high-performance liquid chromatography (UHPLC). This new product aims to enhance trace analysis capabilities, although specific details about its features and benefits are not provided in the article.
Read more →AAgilent to Participate in Jefferies Global Healthcare Conference 2026
Agilent Technologies Inc. announced that CEO Padraig McDonnell and CFO Adam Elinoff will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 3, 2026. The event will take place in New York City at 9:20 EDT. A live audio webcast and replay will be available on Agilent's Investor Relations website.
Read more →AAgilent to Participate in Jefferies Global Healthcare Conference
Agilent is set to participate in the upcoming Jefferies Global Healthcare Conference. This event will provide a platform for Agilent to showcase its innovations and engage with investors. Further details about the company's presentations or specific topics of discussion have not been disclosed.
Read more →AAgilent Names Michael Buckner as Chief Legal Officer
Agilent has appointed Michael Buckner as its new Chief Legal Officer. This leadership change is part of the company's ongoing efforts to strengthen its executive team. Buckner's experience is expected to contribute positively to Agilent's legal strategies and compliance.
Read more →AAgilent to Announce Second-Quarter Fiscal Year 2026 Financial Results on May 27
Agilent Technologies Inc. will release its second-quarter financial results for fiscal year 2026 on May 27, following the market's close. A conference call will be held at 1:30 p.m. PDT to discuss these results. The company reported a revenue of $6.95 billion in fiscal year 2025, reflecting its strong market position.
Read more →AAgilent Showcases Cancer Research Solutions at AACR 2026
Agilent presented its cancer research solutions at the AACR 2026 conference. The showcase highlighted advancements in cancer research technologies. Details on specific solutions or innovations were not provided in the article.
Read more →AAgilent Announces the BioTek Cytation 9 Cell Imaging Multimode Reader
Agilent Technologies has launched the BioTek Cytation 9, a new cell imaging multimode reader. This innovative platform combines advanced imaging capabilities with multimode microplate reading, designed to enhance research workflows. The Cytation 9 aims to support rigorous demands in pharmaceutical and biotechnology labs, offering faster and more adaptable tools for drug discovery and disease research.
Read more →AAgilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Esophageal or Gastroesophageal Junction (GEJ) Carcinoma
Agilent Technologies has received FDA approval for its PD-L1 IHC 22C3 pharmDx as a companion diagnostic for esophageal or gastroesophageal junction carcinoma. This approval allows for the identification of patients whose tumors express PD-L1, making them eligible for treatment with KEYTRUDA. This marks the eighth indication for the diagnostic, further supporting precision medicine in oncology.
Read more →AAgilent to Acquire Biocare Medical, a Global Leader in Clinical and Research Pathology Solutions
Agilent Technologies has announced its acquisition of Biocare Medical for $950 million, aiming to enhance its pathology portfolio. Biocare, a leader in clinical pathology, has experienced significant growth since 2021. The acquisition is expected to positively impact Agilent's revenue and margin profile in its first year. The deal is subject to regulatory approvals and is anticipated to close by late 2026.
Read more →AAgilent Reports First-Quarter Fiscal Year 2026 Financial Results
Agilent Technologies reported a revenue of $1.80 billion for Q1 FY2026, marking a 7.0% increase year-over-year. The company raised its full-year revenue outlook and adjusted its non-GAAP EPS guidance upward. Despite facing challenges such as a significant snowstorm, Agilent's strong performance in core revenue growth and margin expansion reflects its effective customer-focused strategy. The company remains optimistic about its growth prospects.
Read more →AAgilent to Participate in TD Cowen’s 46th Annual Health Care Conference
Agilent Technologies Inc. will participate in TD Cowen's 46th Annual Health Care Conference. CFO Adam Elinoff and Head of Investor Relations Tejas Savant will engage in a fireside chat on March 3, 2026, in Boston. A live audio webcast will be available for those unable to attend in person.
Read more →AAgilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (EOC)
Agilent Technologies has received FDA approval for PD-L1 IHC 22C3 pharmDx, the first companion diagnostic for epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. This diagnostic will help identify patients eligible for KEYTRUDA treatment, enhancing precision medicine in oncology. The approval reflects Agilent's commitment to improving cancer treatment options.
Read more →AAgilent Presents Boehringer Ingelheim With Inaugural 2025 Instrument Trade‑In Impact Award
Agilent Technologies has awarded Boehringer Ingelheim with the inaugural Instrument Trade-In Impact Award for their outstanding sustainability efforts in 2025. The award recognizes the company's leadership in diverting laboratory instruments from landfills, contributing to a circular economy. Boehringer Ingelheim's initiatives resulted in the highest recovery value among Agilent's partners, showcasing their commitment to sustainable practices.
Read more →AAgilent Showcases Next‑Generation Automated Solutions at SLAS2026
Agilent Technologies will present next-generation automated workflow innovations at the SLAS2026 International Conference & Exhibition in Boston. The company will demonstrate its automation ecosystem, featuring advanced imaging and AI-powered optimization tools. Agilent will also debut a compliance-enabling software module and showcase new lab optimization tools. The event highlights Agilent's commitment to advancing laboratory automation.
Read more →AAgilent to Announce First-Quarter Fiscal Year 2026 Financial Results on Feb. 25
Agilent Technologies Inc. will announce its financial results for the first quarter of fiscal year 2026 on February 25, after market close. A conference call will follow at 1:30 p.m. PST to discuss these results. The company reported a revenue of $6.95 billion in fiscal year 2025, showcasing its strong market position.
Read more →AAgilent Accelerates Digital Pathology with the Launch of the Agilent S540MD Slide Scanner System
Agilent Technologies has launched the Agilent S540MD Slide Scanner System, enhancing digital pathology solutions in key European markets. This scanner is designed for high throughput, capable of handling up to 540 slides with automated scanning modes and AI-assisted tissue detection. The introduction aims to improve diagnostic workflows and operational efficiency in pathology laboratories, addressing the growing demand for digital solutions.
Read more →AAgilent Announces 21 CFR Part 11 Compliance Software for xCELLigence RTCA eSight
Agilent Technologies has launched a new 21 CFR Part 11 compliance software for its xCELLigence RTCA eSight system. This upgrade allows the system to be utilized in GMP-regulated environments, enhancing data integrity and audit-readiness. The software includes features such as secure user authentication and electronic signatures, supporting users in both drug discovery and manufacturing settings.
Read more →Competitive Position
How A ranks across every disease it competes inCompetitive Position is a premium feature
See how A ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial